A Clinical Study of MIL95 in Advanced Malignancies. — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
China
Beijing Cancer Hospital, Beijing Last updated November 2024